Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
Executive Summary
Infliximab-abda gains FDA licensure without having faced an advisory committee review; under current case law, launch could come as early as mid-October.
You may also be interested in...
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
Samsung's Biosimilar Manufacturing Documents Lead Janssen To Drop Infringement Suit
Janssen concludes the manufacturing processes for Renflexis do not infringe its Remicade patents, clearing Samsung and partner Merck from potential damages resulting from their at-risk launch of the biosimilar; innovator's legal action remains against Inflectra partners Pfizer and Celltrion.